Tag: Yesafili
GENERAL Biocon Q2 Net Profit Declines 52% To ₹41 Cr; Revenue Up 2% At ₹4,389 Cr

Biocon Ltd, the Bengaluru-based global biopharmaceuticals company, reported a 52% year-on-year decline in consolidated net profit to ₹41 crore for the second quarter of FY27, compared with ₹85 crore in the corresponding quarter last fiscal. Consolidated revenue from operations increased 2% to ₹4,389 crore from ₹4,296 crore a year earlier. Consolidated EBITDA stood at ₹865 […]

CW Bureau · Nov 4, 2026
GENERAL Biocon Launches Interchangeable Eye Drug Biosimilar Yesafili In US Market

Biocon Ltd has commercially launched Yesafili, its interchangeable biosimilar to blockbuster eye drug Eylea (aflibercept) 2 mg, in the United States, marking a significant expansion of its ophthalmology portfolio in the world’s largest pharmaceutical market. Yesafili is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of various retinal disorders, including age-related macular […]

CW Bureau · Aug 3, 2026